The FDA has authorized the first robotic device that can draw blood from an adult's arm with no hands-on involvement from a human operator, and a single trained phlebotomist can supervise three of them at once.
The agency announced on Wednesday the authorization for the Aletta, made by the Dutch company Vitestro. It is cleared for use with adults in outpatient settings and must be operated under the supervision of a supervisor trained in phlebotomy.
Michelle Tarver, director of the FDA's Center for Devices and Radiological Health, framed the reasoning around access rather than novelty, calling blood draws "one of the most commonly performed medical procedures" in the country and noting that patients face delays from a growing shortage of trained phlebotomists.
Inside the Sequence, the Device Runs on Its Own
The machine handles the procedure end-to-end, but a person starts it and stays nearby.
A trained phlebotomist initiates each session and remains available to respond to issues throughout. The device guides the patient to position an arm, and either the patient or the supervisor presses a button to begin. The Aletta then uses near-infrared light and Doppler ultrasound to locate a suitable vein and tell it apart from arteries.
From there, it applies a tourniquet, prepares the skin, inserts the needle, changes collection tubes, disposes of the needle, and places a bandage. The supervising phlebotomist confirms that tubes are filled in the correct order and verifies that all tubes are adequately full afterward, which matters because draw order and fill volume affect the validity of several common tests.
Several safety behaviors are built in. The device continuously applies disinfectant to the skin during the ultrasound scan. If the patient moves too much, the needle automatically detaches and the draw stops. Additional onboard sensors can pause the procedure and alert the supervisor if other unsafe conditions are detected. A trained professional cleans the machine between patients.
One design decision is easy to miss and is arguably the most important. If the device cannot find an appropriate vein, it does not attempt the procedure.
The Qualifier Buried in the Clinical Data
That last point shapes how the performance claim should be read.
The FDA states that the authorization rests on clinical data showing that the Aletta achieves successful blood draw rates comparable to or better than those of trained human phlebotomists when it proceeds with a stick. The agency says this held across patients with varying health statuses and skin tones, and among those with self-reported difficult vein access, and that device-related adverse events were uncommon and mild.
The qualifier is not a criticism of the device. It describes what the comparison measures. A machine that declines the hardest cases and performs well on the ones it accepts is being compared with human phlebotomists who take every patient who sits down.
The published trial data give a sense of how often that happens. In the multicenter stage of the company's pivotal program, the system assessed 1,743 subjects and could not identify a suitable vein in 110 of them, leaving 1,633 in whom it proceeded. Among that group, first-stick success was 94.5%, including 97.4% in patients with a body mass index above 30, 93.4% in patients older than 65, and 92.7% in patients reporting difficult venous access. Those results were published in Clinical Chemistry and form part of the ADOPT trial, registered as NCT05878483. Vitestro funded the study, and several authors are company employees or hold equity.
The authorization came through the De Novo pathway, used for low- to moderate-risk devices of a new type. Additionally, the FDA is establishing special controls covering labeling, performance testing, and clinical testing.
What Changed Since MedicalDaily Reported This Device Was Not Cleared
Two weeks ago, MedicalDaily reported on robotic phlebotomy and feeding tube placement as responses to hospital staffing gaps. That article stated that neither system was cleared by the FDA for autonomous use in the United States, and that Vitestro had said it planned to submit a De Novo application on an undetermined timeline.
That is the fact that has now changed, and it changed faster than the company's own public statements suggested. In April, Vitestro's chief medical officer told the trade press the firm was still determining a timeline for its FDA submission while planning a European commercial launch. The device received a European CE mark in 2024 and has been placed in Dutch and Danish hospitals, though the company said those placements were for use in clinical trials rather than routine service.
The robotic feeding tube system described in that earlier article remains a prototype and is unaffected by this decision.
Patients Are Unlikely to Meet One Soon
Authorization is permission to market, not deployment. No timeline has been announced for US availability, no pricing has been disclosed, and health systems that adopt the technology will need to develop staffing models, maintenance plans, and integration with laboratory information systems.
The company's backers include health systems with a direct interest in the outcome. Its most recent funding round drew investment from the Labcorp Venture Fund, Mayo Clinic, and Sutter Health, and Vitestro has announced a multi-year collaboration with Northwestern Medicine to advance autonomous phlebotomy in the United States.
For a patient, the practical questions are narrow and worth asking if a device appears at an outpatient lab. Whether a human phlebotomist is available on request. Whether the supervising phlebotomist will step in if the machine declines to proceed. Whether the visit costs more.
Nobody should avoid ordered bloodwork over this. Blood draws remain among the safest routine procedures in medicine, performed by either method, and a delayed test carries more risk than the choice of who or what holds the needle.
What remains unknown is how often the device declines a patient outside trial conditions, how it performs at typical outpatient volume, and whether one phlebotomist supervising three machines holds up in practice as well as it does on paper. The special controls attached to this authorization are the mechanism through which those questions get answered, and the FDA's public health pillars framing places the decision under access to medical products rather than under efficiency.
Key Questions Answered
What exactly did the FDA authorize? The Aletta, made by Vitestro, the first standalone robotic device that can draw blood from an adult's arm without hands-on operator intervention. It is authorized for adults in outpatient settings.
Is a human still involved? Yes. A supervisor trained in phlebotomy initiates each session, remains available throughout, and verifies tube order and fill volume afterward. One phlebotomist can oversee up to three devices.
How does it find a vein? Near-infrared light and Doppler ultrasound identify a suitable vein and distinguish it from an artery. If no appropriate vein is found, the device does not attempt the draw.
Does it work as well as a person? The FDA says success rates are comparable to or better than those of trained phlebotomists when the device is used with a stick. In the company's multicenter trial, a suitable vein could not be found in about 6% of subjects assessed.
What happens if I move during the draw? The needle automatically detaches, and the procedure stops. Additional sensors can pause the draw and alert the supervisor.
When will I see one at my lab? No US availability timeline or pricing has been announced. Authorization permits marketing; it does not schedule deployment.
Can I still ask for a human? That will be a decision for individual health systems rather than the FDA. It is reasonable to ask at check-in whether a device is present.
